Treatment

CagriSema (Cagrilintide B and Semaglutide I) clinical trials

Active studies that list CagriSema (Cagrilintide B and Semaglutide I) as an intervention or treatment.

3active studies

0recruiting now

16countries represented

56largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Opening soonPhase 3

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Active, not recruitingPhase 3

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 2

Diabetes Mellitus, Type 2, Diabetic Peripheral NeuropathyCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Canada, Denmark54 locations

Novo Nordisk A/SSponsor

Updated 2025-12-05 · NCT06797869See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.